Drugs / LPH-5
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06722820 | Apr → Nov 2025 overdue | — | Lophora | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-06-10 | Lophora | Results Lophora Announces Positive Phase 1 Topline Results for LPH-5 lophora.com ↗ |
| 2024-09-17 | Lophora | Regulatory Lophora Receives Approval from EMA to Initiate Phase I Clinical Trial for LPH-5, a Promising Treatment for Depression. lophora.com ↗
Lophora has received approval from the European Medicines Agency (EMA) to commence a Phase I, first-in-man, randomized, placebo-controlled, single-dose escalation study for LPH-5. |
| 2024-05-31 | Lophora | Regulatory Lophora Submits Clinical Trial Authorisation (CTA) Application to the French Medicines Agency (ANSM) for lead CNS drug LPH-5. lophora.com ↗
Lophora, a clinical-stage CNS drug discovery company developing novel, next generation 5HT 2A RA medicines to treat a multitude of psychiatric disorders, announced today that it has submitted a Clinical Trial Application (CTA) for its lead drug program LPH-5. |
All press releases naming this drug 8 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LPH-5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06722820 ↗ |